A total of 21 non-surgical metastatic melanoma patients treated with ICI were involved in the study, including anti-PD-1 monotherapy or a combination of anti-PD-1 and anti-CTLA-4 therapy. This evidence concerns the gene CTLA4 and metastatic melanoma.